Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Bmrn save search
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
Published: 2023-09-15 (Crawled : 13:30) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.34%
H: 2.01%
C: 0.89%
voxzogo europe chmp children achondroplasia positive treat
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
europe chmp positive therapy
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults
Published: 2021-07-19 (Crawled : 17:00) - biospace.com/
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
Published: 2021-07-19 (Crawled : 15:00) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -1.84%
H: 2.39%
C: 1.79%
presentation gene therapy positive therapy results phase 3 trial gene therapies
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published: 2021-06-25 (Crawled : 12:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.66%
H: 1.39%
C: 0.55%
treatment europe drop positive children growth chmp achondroplasia
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
Published: 2021-01-10 (Crawled : 00:11) - prnewswire.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -6.61%
H: 1.28%
C: -3.19%
gene therapy positive therapy results phase 3 trial trial results gene therapies
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.